Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

v3.10.0.1
Commitments and Contingencies (Details Textual)
1 Months Ended 12 Months Ended
Dec. 15, 2018
USD ($)
$ / shares
Oct. 09, 2018
Apr. 01, 2018
USD ($)
Dec. 19, 2018
USD ($)
Nov. 26, 2018
USD ($)
$ / shares
Nov. 21, 2018
USD ($)
Nov. 16, 2018
Oct. 31, 2018
Aug. 16, 2017
Jul. 25, 2017
Feb. 17, 2015
Dec. 31, 2014
USD ($)
Jan. 31, 2011
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Aug. 16, 2018
shares
Commitments and Contingencies (Textual)                                
Minimum royalties accrued                           $ 40,000    
Minimum royalties paid                           0    
Performance bonus plan, description                     Under the PBP, 5.25% of the first $14.7 million of a strategic transaction (one or more transactions that provide funds to the Company and/or its members that enable the commencement of the clinical development of AD04) will be set aside for Company’s personnel with 1.25% of funds to be awarded to the Chairman of the Board and the remainder to be awarded at the CEO’s discretion, with no more than 3.15% payout to the CEO of the Company. The maximum bonus amount to be paid out of the PBP was $771,750. The Company had the right to pay up to 65% of the amounts due under the PBP with equity of the Company, valued at a future investors round equity price, with the balance paid in cash in order to potentially pay taxes that may be due by the recipients due to the award under the PBP.          
Shares of common stock                           3,436,406  
Associated charge to operations                           1,500,000    
Employment agreements terms, description                   The Company and the CEO, COO/CFO, and Chief Development Officer upon consummation of the IPO for terms ranging from three to five years, salaries ranging from $325,000 per year to $143,000 per year (at a 50% time commitment), with customary terms of severance. Following the consummation of the IPO on July 31, 2018, the CEO and COO/CFO executed their respective employment agreements.            
Grant incentive plan, description     The Company will make a yearly payment to the Plan Participant, based on the grant funding received by the Company in the preceding year from grants originated by the Plan Participants, in an amount equal to 10% of the first $1 million of grant funding received and 5% of grant funding received in the preceding year above $1 million. Amounts to be paid to the Plan Participants will be paid to each as follows: 50% in cash and 50% in stock no later than March 31, each year.                          
Sublease, description                 The Company has agreed to pay rent in the amount of $300 per month while it is a private company with the rent increasing to $1,300 per month beginning on the first day of the month after it is a public company.              
Rent expense                           3,900 750  
Lyons Capital, LLC [Member]                                
Commitments and Contingencies (Textual)                                
Shares of common stock $ 18,750                              
Shares issued price per share | $ / shares $ 3.46                              
Compensation rate of consulting agreement $ 64,875                              
Consulting agreement, description The engagement has been terminated, the Company will be required to issue 18,750 shares common stock to Lyons on each of March 15, June 15, and September 15, 2019.                              
Securities and Exchange Commission [Member]                                
Commitments and Contingencies (Textual)                                
Shares of equity incentive plan | shares                               1,750,000
Lease Commitments [Member]                                
Commitments and Contingencies (Textual)                                
Monthly payments of lease                       $ 2,250        
Lease terminated                       Terminated on January 31, 2017.        
Security deposit                       $ 2,250        
Rent expense                           0 $ 2,130  
License and Membership Agreement [Member]                                
Commitments and Contingencies (Textual)                                
License agreement description   The Company agreed to pay a monthly fee of $1,152 for membership and use of these facilities, committing to do so for a term of one year.                            
Security deposit                           $ 1,100    
Office Service Agreement [Member]                                
Commitments and Contingencies (Textual)                                
License agreement description                           The agreement was executed, the first use fee for the month of January 2019 of $1,150, a security deposit of $1,150, and a setup fee of $200 became due and payable.    
Monthly payments of lease       $ 1,150                        
Security deposit                           $ 1,150    
Consulting Agreement [Member] | Bespoke Growth Partners, Inc. [Member]                                
Commitments and Contingencies (Textual)                                
Shares of common stock         $ 100,000                      
Shares issued price per share | $ / shares         $ 1.66                      
Compensation rate of consulting agreement         $ 166,000                      
Consulting agreement, description         The agreement has been terminated, the Company will be required to issue 50,000 shares of common stock to Bespoke on each of March 1, June 1, and September 1, 2019.                      
Consulting Agreement [Member] | LWY Consulting, Inc. [Member]                                
Commitments and Contingencies (Textual)                                
Percentage of maximum options to be issued               25.00%                
Mr. Stilley [Member]                                
Commitments and Contingencies (Textual)                                
Shares of common stock     $ 197,673                          
Dr. Johnson [Member]                                
Commitments and Contingencies (Textual)                                
Shares of common stock     50,000                          
Mr. Truluck [Member]                                
Commitments and Contingencies (Textual)                                
Shares of common stock     $ 44,636                          
Master services agreement [Member]                                
Commitments and Contingencies (Textual)                                
Description of master services agreement               The MSA has a term of five years, automatically renewed for two year periods, unless either party gives written notice of a decision not to renew the agreement three months prior to automatic renewal. The agreement can be terminated by the Company if, in the Company's reasonable opinion, clinical or non-clinical data support termination of the clinical research for safety reasons.                
Service Agreemen 1 [Member]                                
Commitments and Contingencies (Textual)                                
Description of master services agreement             The Company and Crown entered into Service Agreement 1 under the MSA for a 24 week, multi-centered, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical study of the Company's lead compound, AD04. The MSA or a service agreement under it may be terminated by the Company, without penalty, on fourteen days written notice.                  
Estimated cost                           2,500,000    
Service Agreemen 1 [Member] | Euro [Member]                                
Commitments and Contingencies (Textual)                                
Estimated cost                           2,172,000    
Service Order [Member]                                
Commitments and Contingencies (Textual)                                
Fee for completion of trial under service                           $ 3,400,000    
Euro/US dollar exchange rate                           1.1444    
Prepayment under the agreement cost           $ 505,961                    
Service Order [Member] | Euro [Member]                                
Commitments and Contingencies (Textual)                                
Fee for completion of trial under service                           $ 2,952,355    
Licensing & Venture Group [Member]                                
Commitments and Contingencies (Textual)                                
License agreement description                         The Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of an NDA by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense ourselves. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income.      
License agreement notice period, description                         The license agreement may be terminated by UVA LVG upon sixty (60) days written notice if the Company breaches its obligations thereunder, including failing to make any milestone, the most immediate being initiating Phase 3 clinical trials by December 31, 2019, making required payments or the failure to exercise diligence to bring licensed products to market.      
License agreement amendment changed dates, description                         This amendment changed the dates by which the Company, using commercially reasonable efforts, was to achieve the goals of submitting a New Drug Application to the FDA for a licensed product to December 31, 2024 (from December 31, 2023) and commencing commercialization of an FDA approved product by December 31, 2025 (from December 31, 2024).